BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 956 shares of BioLife Solutions stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $15.31, for a total transaction of $14,636.36. Following the completion of the transaction, the chief financial officer now owns 126,658 shares in the company, valued at approximately $1,939,133.98. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Troy Wichterman also recently made the following trade(s):
- On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The shares were sold at an average price of $17.83, for a total transaction of $9,271.60.
- On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,288.62.
- On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,682.95.
BioLife Solutions Stock Performance
Stock-Picking AI Predicts #1 Stock of 2024
From Altimetry | Ad
Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.
Click here to learn what's coming (and how to prepare).
NASDAQ:BLFS opened at $17.02 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $771.01 million, a price-to-earnings ratio of -11.20 and a beta of 1.67. The firm's fifty day simple moving average is $17.40 and its 200 day simple moving average is $15.39. BioLife Solutions, Inc. has a twelve month low of $8.92 and a twelve month high of $24.50.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.02. The business had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. As a group, equities research analysts expect that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BioLife Solutions
A number of institutional investors have recently added to or reduced their stakes in BLFS. Nisa Investment Advisors LLC lifted its holdings in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider's stock worth $26,000 after buying an additional 1,020 shares in the last quarter. GAMMA Investing LLC acquired a new position in BioLife Solutions in the 4th quarter worth $41,000. Register Financial Advisors LLC acquired a new position in BioLife Solutions in the 1st quarter worth $96,000. Allspring Global Investments Holdings LLC lifted its holdings in BioLife Solutions by 88.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider's stock worth $157,000 after buying an additional 5,324 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioLife Solutions by 8.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider's stock worth $216,000 after buying an additional 1,164 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a report on Thursday, April 4th. They set a "buy" rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.40.
Check Out Our Latest Research Report on BLFS
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
